We conducted a quantitative structure-activity relationship study using a database of 158 quinolones previously tested against Mycobacterium avium-M. intracellulare complex in order to develop a model capable of predicting the activity of new quinolones against the M. avium-M. intracellulare complex in vitro. Topological indices were used as structural descriptors and were related to anti-M. avium-M. intracellulare complex activity by using the linear discriminant analysis ( Mycobacteria belonging to the Mycobacterium avium-M. intracellulare complex are responsible for opportunistic infections in immunocompromised patients, especially those with HIV infection (29), and there is a need for new drugs that can be used for treatment and prophylaxis. Quinolones are good candidates because of their broad antibacterial spectrum, which includes atypical mycobacteria (16, 22, 25, 30) , together with their good tissue distribution and intracellular concentration (2). Ciprofloxacin and sparfloxacin are the only quinolones currently used against M. avium-M. intracellulare complex infection, but the incidence of strains resistant to these compounds is increasing, and there is a need for new derivatives.
Mycobacteria belonging to the Mycobacterium avium-M. intracellulare complex are responsible for opportunistic infections in immunocompromised patients, especially those with HIV infection (29) , and there is a need for new drugs that can be used for treatment and prophylaxis. Quinolones are good candidates because of their broad antibacterial spectrum, which includes atypical mycobacteria (16, 22, 25, 30) , together with their good tissue distribution and intracellular concentration (2) . Ciprofloxacin and sparfloxacin are the only quinolones currently used against M. avium-M. intracellulare complex infection, but the incidence of strains resistant to these compounds is increasing, and there is a need for new derivatives.
In addition to in vitro and in vivo tests, which are timeconsuming for the M. avium-M. intracellulare complex, powerful methodologies for drug design and drug database screening and selection are now available (7, 19) . Equation systems linking structure and activity (QSAR studies) are particularly relevant, and application of the mathematical models thereby obtained to large libraries of computer-generated compounds is known as virtual computational screening (5, 24 ). An important feature in this method is the use of good structural descriptors that are representative of the molecular features responsible for the relevant biological activity; a very useful technique for describing molecular structure is molecular topology, a two-dimensional QSAR method which takes into account the internal atomic arrangement of compounds. The structure of each molecule is represented by specific subsets of topological indices (TIs). Klopman et al. first developed computer-based predictive models to characterize anti-M. avium-M. intracellulare complex activity (20, 21, 23) . The aim of this study was to develop new QSAR models, based on TIs, statistical linear discriminant analysis (LDA), and multilinear regression (MLR) in order to predict the in vitro activity and MICs of quinolones against the M. avium-M. intracellulare complex.
MATERIALS AND METHODS
The study involved a number of steps, which are described in the following paragraphs.
Obtaining structural descriptors by molecular topology. A database of 158 quinolones with known anti-M. avium-M. intracellulare complex activities has been built up from several articles by Klopman et al. (20, 21, 23) . Each quinolone was characterized by a set of 145 TIs specific to each molecule. We used the topological descriptors provided by MOLCONN-Z software, version 3.50 (L. H. Hall, Eastern Nazarene College, Quincy, Mass.), especially the Kier and Hall connectivity indices (up to the 10th order) and the electrotopological indexes (17, 18) . We also calculated some descriptors as charge indices (11) using Etopo 11, a computer software developed in our research unit.
Statistical treatment: LDA. On the basis of the data of Klopman et al. (20, 21, 23) , the quinolones studied here were separated into active and inactive compounds according to their MICs around a cutoff of 32 g/ml. In accordance with the studies of Klopman et al., this cutoff was selected since it allowed a clear differentiation between active and inactive drugs. LDA was then applied to these two groups (except for 44 quinolones reserved as a test group) in order to obtain a mathematical equation linking structural descriptors and activity. LDA is a pattern recognition method providing a classification model based on the combination of variables that best predicts the category or group to which a given compound belongs. The independent variables in this study were the calculated TIs, and the discrimination property was anti-M. avium-M. intracellulare complex activity. The software used for the LDA study was the BMDP 7M package (W. J.
Dixon, BMDP Statistical Software, University of California, Berkeley), which randomly chooses the compounds reserved for the test set. The variables used to compute the linear classification functions are chosen in stepwise manner: at each step the variable that makes the larger contribution to the separation of the groups is entered into the discriminant equation (or the variable that makes the smallest contribution is removed). The method used to select the descriptors was based on the F-Snedecor parameter, which allows the assessment of relative importance among the candidate variables (8, 15) . The classification criterion was the minimal Mahalanobis distance, which is the distance of each case to the mean of all cases used in the regression equation (15) . The quality of the discriminant equation was evaluated using Wilk's U-statistical parameter, a multivariate analysis of variance that tests the equality of group means for the variable(s) in the discriminant equation (15) .
PDDs. Pharmacological distribution diagrams (PDDs) were constructed to determine the intervals of the equation in which the probability of finding active compounds increases (9) . PDDs are histograms of calculated values of the mathematical functions in which expectancies appear on the ordinate axis. For an arbitrary interval of values of a given function, we can define an expectancy of activity as E a ϭ a/(i ϩ 1), where a is the number of active compounds in the interval divided by the total number of active compounds and i is the number of inactive compounds in the interval divided by the total number of inactive compounds. The expectancy of inactivity is defined in a symmetrical way as E i ϭ i/(a ϩ 1). This representation provides good visualization of the regions of minimum overlap and selects regions in which the probability of finding improved compounds is maximum.
Pharmacological tests. Twenty-four quinolones that had not been used for the LDA analysis were evaluated with the model in order to establish their potential activities against the M. avium-M. intracellulare complex. These quinolones were selected as having structures representative of the main quinolone structures, including the most recently developed fluoroquinolones (3, 6) . In parallel, in vitro studies were performed with the MO-1 strain of M. avium, which was isolated from the blood of a patient with AIDS and which has already been used for in vitro drug susceptibility studies (27) . We used the Alamar blue susceptibility test described by Collins and Franzblau (4) . This technique uses an oxidation-reduction dye which is an indicator of cell growth and/or viability. The inoculum was prepared from a subculture of M. avium in 10 ml of Middlebrook 7H9 broth containing 0.2% (vol/vol) glycerol, 0.05% (vol/vol) Tween 80, and 10% albumin-dextrose-catalase (ADC) (Difco Laboratories, Detroit, Mich.). The cultures were used after 7 days of incubation at 37°C with 5% CO 2 . Initial drug dilutions were prepared in the appropriate medium, and subsequent twofold dilutions were made in 0.1 ml of 7H9 broth (plus glycerol and ADC) in 96-well microplates. Control wells consisted of medium alone (0.2 ml) and bacteria alone (0.1 ml of medium plus 0.1 ml of bacteria; final density, 2 ϫ 10 5 CFU/well). Bacteria (0.1 ml) were added to the wells containing the drug dilutions. Each test was run in duplicate, and control experiments were done with the solvent alone. After 4 days of culture at 37°C with 5% CO 2 , 20 l of 10ϫ Alamar blue solution (Interchim, Montluçon, France, or Alamar Biosciences Inc., Sacramento, Calif.) was added to one medium control well and one bacterial control well, and the plates were further incubated for 24 h. When the color changed in the bacterial well (from the blue oxidized form to the pink reduced form), Alamar blue was added to the other wells and plates were incubated for 24 h. Results were read on a spectrophotometer at wavelengths of 540 and 620 nm using an automatic plate reader (Labsystems Multiskan RC, Helsinki, Finland) interfaced to a Macintosh computer. Percent inhibition was calculated as (1 Ϫ mean test well optical density [OD]/mean bacterial well OD) ϫ 100. The MIC was the lowest drug concentration yielding at least 90% inhibition. Results obtained in preliminary experiments with anti-M. avium-M. intracellulare complex antibiotics (rifampin, clarithromycin, rifabutin) and quinolones (ofloxacin and sparfloxacin) were in agreement with those obtained by Collins and Franzblau (4).
MLR.
A correlation between the calculated and observed MICs of the 24 quinolones tested was obtained by MLR in order to predict the MICs of new quinolones. The MLR was performed with the 9R module of the BMDP program, which estimates regression equations for best subsets of predictor variables and provides detailed residual analysis. The lower Mallows' Cp was used to identify the best subsets in accordance with the equation Mallows' Cp ϭ RSS/ s 2 Ϫ (n Ϫ 2pЈ), where RSS is the residual sum of squares for the best subset being tested, pЈ is the number of independent variables in the subset (including the intercept), n is the number of cases, and s 2 is the residual mean square based on the regression using all independent variables (26).
FIG. 1. General structure of the quinolones. X and Y can be carbon or nitrogen atoms, and the R1, R5, R6, R7, and R8 groups can be very diverse structures. Virtual computational screening. Computational screening was used to determine the influence of quinolone substituents on anti-M. avium-M. intracellulare complex activity. Virtual structures obtained by omission or substitution of radicals R1, R6, R7, or R8 on the three most active quinolones were designed (Fig.  1) . Their TIs were calculated, and LDA and MLR equations were applied to predict anti-M. avium-M. intracellulare complex activity or inactivity and MICs.
RESULTS

LDA.
Using a MIC cutoff of 32 g/ml, the following equation The values of the discriminant function M and the corresponding prediction of activity or inactivity are presented in Table 1 for the training group and in Table 2 for the test group. In the training group (114 compounds), 51 of the 57 active compounds (89.5%) and 49 of the 57 inactive compounds (86.0%) were correctly classified. In the test group, which comprised 44 randomly chosen quinolones, 23 of the 27 active compounds (85.2%) and 14 of the 17 inactive compounds (82.4%) were correctly classified. Overall, the rate of correct classification was 86.7%.
A good example of the discriminating capacity of the model was the result obtained with two quinolones which have the same molecular weight and large structural similarities but different anti-M. avium-M. intracellulare complex activities. The M function was 1.77 for PD139586, which is active in vitro, and Ϫ0.75 for PD138362, which is inactive (Fig. 2) .
The pharmacological activity distribution diagrams (Fig. 3 ) show that for M values between Ϫ1 and 1.5 the classification of the drugs is uncertain, because of marked overlap of M values of several active and inactive drugs. In contrast, the highest activity expectancy occurred at M values Ͼ1.5. As our principal objective was to define a clear-cut difference between active and inactive quinolones, we assumed that quinolones with M values Ͼ1.5 were active and those with M values ϽϪ1 were inactive. Quinolones with M values between Ϫ1 and 1.5 were considered nonclassified.
When these criteria were applied to the 158 quinolones, only 2 of 50 compounds in the training group (PD125639 and PD127275) and 3 of 23 compounds in the test group (PD129626, PD135305, and PD141494) had M values Ͼ1.5 even though they were inactive in vitro. This meant that a cutoff of M ϭ 1.5 yielded overall rates of correct classification of quinolones predicted as active of 96.0% in the training group and 87.0% in the test group.
Predicted and observed activities of 24 commercial quinolones. The activities of 24 quinolones that had not been used to calculate the mathematical model were estimated, and the results were compared to those subsequently obtained in vitro (Alamar blue tests). Sixteen compounds were classified ( Table  3 ). Assuming that a drug was inactive if it had a MIC of Ͼ10 g/ml, 15 quinolones were correctly classified as active or inactive. The seven compounds that were predicted as active showed in vitro activity at low concentrations (between 0.2 and 5.4 g/ml). Among the quinolones that were predicted as inactive, only lomefloxacin was misclassified.
MLR and virtual computational screening. Based on the results of in vitro MICs, we used the MLR statistical technique to define a mathematical model able to correlate experimental Table 4 , and their correlation is represented graphically in Fig. 4 . The most-active quinolones were moxifloxacin, sparfloxacin, and gatifloxacin, with MICs of 0.2, 0.4, and 0.9 g/ml, respectively, suggesting that the best structural characteristics for anti-M. avium-M. intracellulare complex activity are a quinoline basic nucleus, a fluorine atom at R6, a cyclopropyl group at N-1, and nucleophilic groups (F or OCH 3 ) at R8.
As the LDA and MLR equations were reliably predictive of in vitro activity, they were then applied to virtual structures derived from the three quinolones most active against M. avium-M. intracellulare complex (moxifloxacin, sparfloxacin, and gatifloxacin) by removing or substituting significant radicals. Initial analysis by LDA showed the crucial importance of the N-1 position, as omission of the cyclopropyl radical implied LDA values that were Ͻ0 for the three drugs, i.e., anti-M. avium-M. intracellulare complex inactivity. The other changes were less determinant, yielding positive LDA values, and a more accurate analysis was conducted with the MLR technique ( Table 5 ). Replacement of the N-1 cyclopropyl by tert-butyl or 2,4-difluorophenyl radicals implied similar or lower MICs. Deletion of R6 resulted in a three-to fivefold increase in the MIC but not in a complete loss of activity. Piperazine or an equivalent group on R7 was determinant for anti-M. avium-M. intracellulare complex activity, as its replacement by a simple pyrrolidinyl or 3Ј-amino-pyrrolidinyl radical resulted in predicted MICs 2 to 18 times higher. Similarly, the presence of R8 seemed essential for activity, because its omission implied a very large increase in the MIC in every case.
DISCUSSION
Molecular topology is a very useful tool for describing molecular structures and has been used for efficient analysis of QSAR data (10) . This method has proven its utility for the prediction of diverse physical, chemical, and biological properties in different groups of compounds (14) and has also been used with success for the design of new drugs (10, 12, 13) . In previous studies Klopman et al. developed a MULTICASE fragment approach that was used to analyze the structureactivity relationships of quinolones against mycobacteria and to discriminate between active and inactive compounds (23) . Using LDA, we have confirmed that molecular-topology methods can reliably discriminate between drugs according to their in vitro activities. In addition we show that MICs of active compounds can also be predicted using an MLR model.
LDA on a panel of 158 active and inactive quinolones correctly classified 96 and 87% of the quinolones predicted as active in the training group and test group, respectively, showing the excellent predictive capacity of the model. When LDA was applied to 24 commercial quinolones that had not been used to define the model and whose MICs were subsequently determined in vitro, 16 quinolones were assigned to the active or inactive group and 15 showed the expected activity or inactivity. Eight quinolones were not classified because of interme- diate M values from the LDA equation, but it should be noted that these drugs also had intermediate in vitro activities. The most important result was the correct prediction of seven active quinolones which had low in vitro MICs, and specially the correct prediction of three of them (moxifloxacin, sparfloxacin, and gatifloxacin) which had MICs of Ͻ1 g/ml.
In addition to the ability of a model to discriminate between active and inactive compounds, we considered it important that a model be able to predict the effective concentration of quinolones against M. avium. For this purpose, an MLR analysis was developed. It was applied to the in vitro values of the 24 quinolones and defined an equation which accurately correlated experimental and calculated MICs (r 2 ϭ 0.88). Furthermore, the very good predictive capacity was confirmed by a cross-validation test (r 2 cv ϭ 0.82). In conclusion, we consider that a combination of structural description by using TIs and statistical treatment by LDA and MLR can reliably select new quinolones effective against the M. avium-M. intracellulare complex. The obtained prediction models can readily be applied to large databases of quinolones to identify active structures and to estimate MICs.
In addition, the combination of LDA and MLR proved useful to investigate the influence of different quinolone radicals on anti-M. avium-M. intracellulare complex activity. The role of several radicals in quinolone activity has already been demonstrated by Klopman et al. (20, 23) , but using MLR allowed estimates of their influence on MICs. Virtual structures were designed from modifications of moxifloxacin, sparfloxacin, and gatifloxacin, and their TIs were calculated. A first Klopman (20) to test the effectiveness of these groups. A loss of activity was found when the R6 position was not occupied by an F atom, confirming the importance of this radical, which is suspected to be involved in cellular penetration. Nevertheless, its influence could be less than that on other bacteria, since some activity was found against the M. avium-M. intracellulare complex. Anti-M. avium-M. intracellulare complex activity was theoretically decreased by a pyrrolidinyl group or a 3Ј-amino-pyrrolidinyl group relative to the original groups in R7: a 3Ј-methyl-piperazinyl group (gatifloxacin), a 3Ј,5Ј-dimethyl-piperazinyl group (sparfloxacin), and a pyrrolidinyl group attached to a six-member ring (moxifloxacin). Finally, the determining role of nucleophilic substituents such as F and OCH 3 radicals on R8 was demonstrated, as its suppression resulted in a very marked increase in estimated MICs. These results may reflect a unique characteristic of the anti-M. avium-M. intracellulare complex activity of quinolones compared to their activity against other bacteria, in which the influence of the R7 and R8 positions is less marked. On the basis of these results, these predictive models might prove useful in the design of new quinolones with improved anti-M. avium-M. intracellulare complex activity, providing considerable cost savings relative to in vitro and in vivo experimental models (1). a R1 and R7 suppression has no sense, as all the quinolones used in the study had a substituent at these positions.
